See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

CSPC’s SYS-6041 cleared to enter clinic in China

Jan. 13, 2025
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYS-6041, an antibody-drug conjugate, for advanced solid tumors.
BioWorld Science Regulatory Cancer Antibody-drug conjugate Immuno-oncology NMPA